Hengrui Therapeutics
Princeton
About Hengrui Therapeutics
HTI is a U.S. biopharmaceutical company dedicated to developing and commercializing innovative drugs to address unmet medical needs. HTI’s current therapeutic areas of focus are oncology and endocrinology, with multiple clinical-stage assets for oncology/immuno-oncology and diabetes/weight loss in the pipeline.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $100.0M
- Funding stage: Private Equity
- Last round: Private Equity (Jun 2016)
- Website: hengruitherapeutics.com
- Phone: (609)423-2155
Industries & Categories
Biopharma, Diabetes, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/hengrui-therapeutics-91021 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.